Offer ease of administration
with Velphoro

Dr. Shori demonstrates how easy it is to break the tablets.

Sandeep K. Shori, DO
Chief of Medicine and Director of Dialysis
Baylor All Saints Medical Center, Fort Worth, Texas

Recommended starting dose is 1 tablet per meal1

Easy to chew

Easy to crush

With Velphoro,
patients control the
size and consistency
of what they can
In vitro study suggested Velphoro is*
  • As chewable as calcium carbonate, and easier to chew than lanthanum carbonate tablets2
  • Designed to disintegrate in the stomach quickly in 7-16 minutes2

Velphoro must be chewed or crushed

More patients than ever have access

learn more >




More patients than ever have access

learn more >


*Study evaluated different mechanical test procedures for assessing tablet chewability, including standard breaking force, strength testing, and new procedures simulating chewing action. A further objective was to apply these tests to assessing the chewability of various formulations of Velphoro compared with that of lanthanum-based and calcium-based phosphate binders.2

1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2018. 2. Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623-1631.


Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.


  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451